Portal de Periódicos da CAPES

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

2024; BMJ; Volume: 12; Issue: 8 Linguagem: Inglês

10.1136/jitc-2024-008872

2051-1426

Michael Schenker, Mauricio Burotto, Martin Eduardo Richardet, Tudor‐Eliade Ciuleanu, Anthony Gonçalves, Neeltje Steeghs, Patrick Schöffski, Paolo A. Ascierto, Michele Maio, Iwona Ługowska, Lorena Lupinacci, Alexandra Léary, Jean‐Pierre Delord, Julieta Grasselli, David S.P. Tan, Jennifer Friedmann, Jacqueline Vuky, Marina Tschaika, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Georgia Kollia, Misena Pacius, Quyen Duong, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola,

Lung Cancer Treatments and Mutations

Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy of nivolumab+ipilimumab in multiple tumor types based on TMB status evaluated using either tumor tissue (tTMB) or circulating tumor DNA in the blood (bTMB).